Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Treprostinil Extension in PH-HFpEF
NCT03043651Phase 3Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2018
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary hypertension (PH), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term Safety of Oral Treprostinil (Adverse Events). Started Jan 2018; status: terminated.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03043651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043651.